Enanta Pharmaceuticals (ENTA) Assets Average (2013 - 2026)

Enanta Pharmaceuticals (ENTA) has 14 years of Assets Average data on file, last reported at $322.1 million in Q1 2026.

• Quarterly Assets Average fell 4.08% year-over-year to $322.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $322.1 million (down 4.08% YoY) and the FY2025 annual result came in at $328.7 million, down 21.64% from the prior year.
• Assets Average improved to $322.1 million in Q1 2026, from $305.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $478.7 million in Q3 2023 to a low of $290.9 million in Q3 2025.
• A 5-year average of $375.1 million and a median of $380.3 million in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average climbed 25.88% — and 2025, when it declined 24.98%.
• Tracing ENTA's Assets Average over 5 years: stood at $361.5 million in 2022, then rose by 23.21% to $445.4 million in 2023, then retreated by 18.58% to $362.6 million in 2024, then fell by 15.86% to $305.1 million in 2025, then gained by 5.57% to $322.1 million in 2026.
• The last three Assets Average figures came in at $322.1 million (Q1 2026), $305.1 million (Q4 2025), and $290.9 million (Q3 2025), per Business Quant data.